scispace - formally typeset
Open AccessJournal ArticleDOI

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies.

TLDR
This work investigated the development of resistance against four antibodies to the spike protein that potently neutralize SARS-CoV-2, individually as well as when combined into cocktails.
Abstract
Antibodies targeting the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) present a promising approach to combat the coronavirus disease 2019 (COVID-19) pandemic; however, concerns remain that mutations can yield antibody resistance. We investigated the development of resistance against four antibodies to the spike protein that potently neutralize SARS-CoV-2, individually as well as when combined into cocktails. These antibodies remain effective against spike variants that have arisen in the human population. However, novel spike mutants rapidly appeared after in vitro passaging in the presence of individual antibodies, resulting in loss of neutralization; such escape also occurred with combinations of antibodies binding diverse but overlapping regions of the spike protein. Escape mutants were not generated after treatment with a noncompeting antibody cocktail.

read more

Citations
More filters
Journal ArticleDOI

COVID-19 vaccination: The impact on the selection criteria of the convalescent plasma donors.

TL;DR: In this paper, the authors proposed a protocol for COVID-19 convalescent plasma (CCP) therapy, which has emerged as an important investigational therapy in the management of CoV-19 patients.
Journal ArticleDOI

A rapid cell-free expression and screening platform for antibody discovery

TL;DR: In this paper , a cell-free DNA template generation, cellfree protein synthesis, and binding measurements of antibody fragments is proposed to accelerate the discovery and characterization of antibodies for future pandemics and for research, diagnostic and therapeutic applications more broadly.
Journal ArticleDOI

Use of Casirivimab and Imdevimab for the Treatment of COVID-19

TL;DR: The authors present three cases of unvaccinated coronavirus disease 2019 (COVID-19) patients who exhibited symptoms of fever, sore throat, nausea, diarrhea, congestion, and headache and presented for the casirivimab and imdevimab monoclonal antibody cocktail, which resulted in the resolution of all symptoms.
References
More filters
Journal ArticleDOI

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2.

TL;DR: Cryo–electron microscopy structures of full-length human ACE2 in the presence of the neutral amino acid transporter B0AT1 with or without the receptor binding domain (RBD) of the surface spike glycoprotein of SARS-CoV-2 are presented, providing important insights into the molecular basis for coronavirus recognition and infection.
Journal ArticleDOI

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2.

TL;DR: The crystal structure of the C-terminal domain of SARS-CoV-2 (SARS- coV- 2-CTD) spike (S) protein in complex with human ACE2 (hACE2) is presented, which reveals a hACE2-binding mode similar overall to that observed for SARS -CoV.
Journal ArticleDOI

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.

TL;DR: Several monoclonal antibodies that target the S glycoprotein of SARS-CoV-2, which was identified from memory B cells of an individual who was infected with severe acute respiratory syndrome coronavirus (SARS- coV) in 2003, and one antibody (named S309) potently neutralization, which may limit the emergence of neutralization-escape mutants.
Related Papers (5)